Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Inclusion Criteria: - Informed consent obtained before any trial-related activities.
Trial-related activities are any procedures that are carried out as part of the trial,
including activities to determine suitability for the trial except for protocol described
pre-screening activities which require a separate informed consent. - Male or female, aged
18-75 years (both inclusive) (for Japan: male or female aged 20-75 years (both inclusive))
at the time of signing informed consent - Local histological diagnosis of NASH followed by
histological confirmation of NASH based on central pathologist evaluation of a liver biopsy
obtained up to 21 weeks before screening - Histologic evidence of NASH based on central
pathologist evaluation of a liver biopsy obtained up to 21 weeks before screening. - NASH
fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system based on central
pathologist evaluation Exclusion Criteria: - Known or suspected abuse of alcohol (above 20
g/day for women or above 30 g/day for men), alcohol dependence* or narcotics. (* = assessed
by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)) - Diagnosis of type
1 diabetes according to medical records - HbA1c above 10% at screening - History or
presence of pancreatitis (acute or chronic) - Calcitonin equal or above 50 ng/L at
screening - Family or personal history of multiple endocrine neoplasia type 2 or medullary
thyroid carcinoma. Family is defined as a first degree relative - Body Mass Index (BMI) ≤
25.0 kg/sqm at the screening visit (visit 1) - Female who is pregnant, breast-feeding or
intends to become pregnant or is of childbearing potential and not using an adequate
contraceptive method (adequate contraceptive measures as required by local regulation or
practice)